Carb-x
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
771e Commonwealth Ave, Boston, Massachus...Website
www.carb-x.orgRevenue
$8.4 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Carb-x
CARB-X accelerates global antibacterial innovation by supporting the development of new antibiotics and other life-saving products to combat dangerous drug-resistant bacteria. The organization focuses on creating a diverse pipeline of early-stage antibiotics, preventatives, rapid diagnostics, and other products aimed at preventing, diagnosing, and treating life-threatening bacterial infections. CARB-X collaborates with various partners and invests significantly in innovative projects across multiple countries. Their mission is to ensure that effective treatments are available globally, addressing the urgent challenge of antibiotic resistance.Explore more
Carb-x Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Carb-x your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Carb-x is spiking on competitors!
Carb-x, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Carb-x had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Carb-x launches new products
Earning: See what the market has to say on Carb-x recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Carb-x
Check if Carb-x has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Carb-x has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Carb-x
Compare insights from companies similar to Carb-x, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$21.8M
51-200
Private
-
2011
HN
Hideaki NomuraCEO JSR Life Sciences Corporation General Manager, Bioprocess Department, Life Science Division JSR Corporation
Company Profile Activity
Activity Insights
Carb-x is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Carb-x is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Carb-x.
Carb-x Tech Stack
A closer look at the technologies used by Carb-x
Most Recent Scoops
Project
Spending/Investment
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Project
Spending/Investment
Open Position
Carb-x News & Media
Seres Therapeutics to Present at CARB-X Investor Day
CAMBRIDGE, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that it will present at the 2026 CARB-X Investor Day on April 16, 2026, which precedes the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global conference in Munich, Germany. CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) is a global nonprofit partnership acceleratBasilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420
Ad hoc announcement pursuant to Art. 53 LRCARB-X receives $60 million from Wellcome to support early-stage antibiotic R&D - CIDRAP
The money will help CARB-X continue its efforts to support development of innovative new antibiotics, preventatives, alternative treatments, and rapid diagnostics for drug-resistant bacteria.CARB-X funds microbiome therapeutic for ICU patients | CIDRAP
Seres Therapeutics will receive up to $3.6 million to advance development of a liquid formulation of SER-155, its investigational microbiome drug.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Carb-x
Sign Up For FreeTo access detailed company insights
CARB-X accelerates global antibacterial innovation by supporting the development of new antibiotics and other life-saving products to combat dangerous drug-resistant bacteria. The organization focuses on creating a diverse pipeline of early-stage antibiotics, preventatives, rapid diagnostics, and other products aimed at preventing, diagnosing, and... Read More
